News

Flow-SuperRCA is a new, ultra-sensitive test to detect the D816V KIT mutation in patients with SM and other mast cell conditions.

A woman with difficulty swallowing and weight loss was initially thought to have a gastrointestinal condition, but was later diagnosed with SM.

Well-differentiated systemic mastocytosis (WDSM), a rare SM variant, was recently associated with previously unknown genetic mutations.

Drug-induced reactions such as anaphylaxis are possible in patients with SM, but recent data suggests that the risk is relatively low.

SM is a risk factor for the development of respiratory symptoms, regardless of whether it presents as indolent SM or advanced SM.

There have been significant advances in the diagnosis and treatment of indolent SM in recent years, although more research is still necessary.

Midostaurin can be an effective therapy in the management of aggressive systemic mastocytosis.

A new expanded access program (EAP) has been launched for patients with SM, allowing eligible patients to receive bezuclastinib.

A Phase 2 clinical study called Apex is currently evaluating the safety and efficacy of bezuclastinib in patients with advanced SM.

Mast cells in patients with systemic mastocytosis (SM) appear to express increased levels of galectin-3 and galectin-8.